Abcam, ab259097, Human SCAF11 (SFRS2IP) knockout HeLa cell lysate

Size: 1Kit
SCAF11 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon10 and 2 bp deletion in exon10.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon10 and 2 bp deletion in exon10.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SCAF11, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SFRS2IP also known as SFRS2-interacting protein and Cisplatin Resistance-Associated Overexpressed Protein (CRISP-1) is a protein with a relative mass of around 92 kilodaltons. It primarily interacts with the serine/arginine-rich splicing factor 2 (SFRS2) as indicated by its name. Researchers have found SFRS2IP mainly in the nucleus of cells where it plays a significant role in pre-mRNA splicing. Studies show its expression in various tissues but it is especially present in actively dividing cells.
Biological function summary
Proteins like SFRS2IP contribute to the regulation of RNA processing and stability. SFRS2IP participates in the spliceosome complex facilitating correct splicing and maturation of precursor mRNA into mature RNA. This process is essential for gene expression regulation ensuring that proteins are synthesized properly and in necessary amounts. SFRS2IP's involvement in these processes influences cell cycle progression and can impact cellular responses to environmental changes.
Pathways
Several studies have included SFRS2IP in processes related to mRNA splicing and gene expression. It is closely connected to the spliceosome pathway where it cooperates with SFRS2 and other splicing factors contributing to proper intron removal and exon joining in precursor mRNA. The protein also interacts with components of the RNA transport pathway ensuring the correct delivery of mRNA to the ribosome for translation.
Scientists have linked SFRS2IP to cancer and drug resistance mechanisms. Elevated expression levels of this protein have been observed in certain neoplastic tissues suggesting a role in tumorigenesis. It is associated in pathways involving oncogenic proteins like SFRS2 which influence cell proliferation and survival. Additionally studies have highlighted a connection between this protein and cisplatin resistance where SFRS2IP may interact with DNA repair proteins to modulate the cellular response to chemotherapy.